FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085880083> ?p ?o ?g. }

• W2085880083 endingPage "1601" @default.
• W2085880083 startingPage "1600" @default.
• W2085880083 abstract "In a recent letter, Garcia Rodriguez LA et al. [1García Rodríguez L.A. Patrignani P. González‐Pérez A. Risk of myocardial infarction persisting after discontinuation of non‐steroidal anti‐inflammatory drugs in the general population.J Thromb Haemost. 2009; 7: 892-4Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar] provide additional information on the risk of acute myocardial infarction (AMI) after discontinuing non‐steroidal anti‐inflammatory drugs (NSAIDs). The data were retrieved from THIN, a database of primary care records in the United Kingdom [2Garcia Rodriguez L.A. Tacconelli S. Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti‐inflammatory drugs in the general population.J Am Coll Cardiol. 2008; 52: 1628-36Crossref PubMed Scopus (0) Google Scholar]. Among patients who had previously used NSAIDs for more than 1 year, the authors found that the risk of AMI remained increased during 3 (relative risk, RR, 1.74; 95% CI, 1.34–2.26) or 6 (RR, 1.61; 95% CI, 0.94–2.76) months after discontinuation, but returned to background risk thereafter (RR, 1.07; 95% CI, 0.64–1.81). They hypothesize a structural effect of long‐term use of NSAIDs on the arterial wall or the genesis of arteriosclerosis, which would take at least 6 months to revert. We would like to offer a more mundane alternate explanation, that of persistent exposure to NSAIDs. Many pharmacoepidemiological studies use prescription data as a surrogate to assess drug exposure. It allows estimation of exposure to drugs when there is no possibility to confirm the patient’s real drug intake. Though this is most likely appropriate for chronically and regularly used drugs such as antihypertensives or antidiabetic drugs [3Noize P. Bazin F. Dufouil C. Lechevallier‐Michel N. Ancelin M.L. Dartigues J.F. Tzourio C. Moore N. Fourrier‐Réglat A. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study.Pharmacoepidemiol Drug Saf. 2009; 18: 310-9Crossref PubMed Scopus (0) Google Scholar, 4Monster T.B. Janssen W.M. De Jong P.E. De Jong‐van den Berg L.T. PREVEND Study GroupPrevention of REnal and Vascular ENT Stage Disease. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool.Pharmacoepidemiol Drug Saf. 2002; 11: 379-84Crossref PubMed Scopus (0) Google Scholar], it has been shown that prescription or even drug delivery data from reimbursement databases were not really trustworthy to measure exposure for drugs with intermittent, symptom‐driven use such as NSAIDs [3Noize P. Bazin F. Dufouil C. Lechevallier‐Michel N. Ancelin M.L. Dartigues J.F. Tzourio C. Moore N. Fourrier‐Réglat A. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study.Pharmacoepidemiol Drug Saf. 2009; 18: 310-9Crossref PubMed Scopus (0) Google Scholar, 5Moore N. Diris H. Martin K. Viale R. Fourrier A. Moride Y. Bégaud B. NSAID use profiles derived from reimbursement data in France.Therapie. 2004; 59: 541-6Crossref PubMed Scopus (17) Google Scholar]. The fact that the persisting increased risk reported by Garcia Rodriguez LA et al. appeared mainly for long‐term use (i.e. more than 1 year) could be explained by an unrecognized persistent use of NSAIDs after the end of the prescription period. This could occur through self‐medication using the stockpiled prescribed NSAIDs, medication purchased OTC [6MacDonald T.M. Morant S.V. Robinson G.C. Shield M.J. McGilchrist M.M. Murray F.E. McDevitt D.G. Association of upper gastrointestinal toxicity of non‐steroidal anti‐inflammatory drugs with continued exposure: cohort study.BMJ. 1997; 315: 1333-7Crossref PubMed Google Scholar] or even that prescribed to other people [7De Bolle L. Mehuys E. Adriaens E. Remon J.P. Van Bortel L. Christiaens T. Home medication cabinets and self‐medication: a source of potential health threats?.Ann Pharmacother. 2008; 42: 572-9Crossref PubMed Scopus (0) Google Scholar]. French data have shown that for osteoarthritis, the main indication for long‐term exposure to NSAIDs, the average real‐life use is only about one‐third of the daily defined dose used for the assessment of prescription‐ or delivery‐based exposure [5Moore N. Diris H. Martin K. Viale R. Fourrier A. Moride Y. Bégaud B. NSAID use profiles derived from reimbursement data in France.Therapie. 2004; 59: 541-6Crossref PubMed Scopus (17) Google Scholar]. This could be particularly important, as Garcia Rodriguez LA et al. did not explicitly define continuous use. In absence of this definition, it is possible to imagine an unrecognized prolonged NSAID exposure after the end of prescription coverage because of intermittent self‐treatment with leftover drugs [6MacDonald T.M. Morant S.V. Robinson G.C. Shield M.J. McGilchrist M.M. Murray F.E. McDevitt D.G. Association of upper gastrointestinal toxicity of non‐steroidal anti‐inflammatory drugs with continued exposure: cohort study.BMJ. 1997; 315: 1333-7Crossref PubMed Google Scholar]. This eventuality has previously been used by McDonald et al. [6MacDonald T.M. Morant S.V. Robinson G.C. Shield M.J. McGilchrist M.M. Murray F.E. McDevitt D.G. Association of upper gastrointestinal toxicity of non‐steroidal anti‐inflammatory drugs with continued exposure: cohort study.BMJ. 1997; 315: 1333-7Crossref PubMed Google Scholar] to justify an unexplainable persistent risk of gastrointestinal bleeding after 1 year from cessation of apparent exposure to NSAIDs. It is also hard to imagine in clinical practise that a patient who continuously took an NSAID for 1 year or more would completely stop using it for the next 6 months, unless this hypothetical patient underwent a surgical replacement of the hip or the knee. It would be consequently interesting to know the most frequent indications for NSAIDs in the THIN study, in particular for those patients in which myocardial infarction occurred after treatment withdrawal. In any case, exposure to NSAIDs may also persist through OTC medication that is ignored in both primary care and claims databases [3Noize P. Bazin F. Dufouil C. Lechevallier‐Michel N. Ancelin M.L. Dartigues J.F. Tzourio C. Moore N. Fourrier‐Réglat A. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three‐City (3C) Study.Pharmacoepidemiol Drug Saf. 2009; 18: 310-9Crossref PubMed Scopus (0) Google Scholar, 5Moore N. Diris H. Martin K. Viale R. Fourrier A. Moride Y. Bégaud B. NSAID use profiles derived from reimbursement data in France.Therapie. 2004; 59: 541-6Crossref PubMed Scopus (17) Google Scholar, 6MacDonald T.M. Morant S.V. Robinson G.C. Shield M.J. McGilchrist M.M. Murray F.E. McDevitt D.G. Association of upper gastrointestinal toxicity of non‐steroidal anti‐inflammatory drugs with continued exposure: cohort study.BMJ. 1997; 315: 1333-7Crossref PubMed Google Scholar] and constitutes a particular issue in studies focusing on NSAIDs [8Kaufman D.W. Kelly J.P. Rosenberg L. Anderson T.E. Mitchell A.A. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey.JAMA. 2002; 287: 337-44Crossref PubMed Google Scholar, 9Amoako E.P. Richardson‐Campbell L. Kennedy‐Malone L. Self‐medication with over‐the‐counter drugs among elderly adults.J Gerontol Nurs. 2003; 29: 10-5Crossref PubMed Google Scholar]. A European survey has shown that about one‐third of patients in the United Kingdom affected by chronic pain had used OTC medication in the preceding 6 months, of which 47–63% were NSAIDs [10Breivik H. Collett B. Ventafridda V. Cohen R. Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment.Eur J Pain. 2006; 10: 287-333Crossref PubMed Scopus (3478) Google Scholar]. Furthermore, it could be simple to ask for and receive from neighbours, relatives or friends an NSAID painkiller for immediate use [7De Bolle L. Mehuys E. Adriaens E. Remon J.P. Van Bortel L. Christiaens T. Home medication cabinets and self‐medication: a source of potential health threats?.Ann Pharmacother. 2008; 42: 572-9Crossref PubMed Scopus (0) Google Scholar]. As a consequence, regardless of their legal status, the most popular self‐administered substances were ibuprofen, diclofenac and piroxicam [7De Bolle L. Mehuys E. Adriaens E. Remon J.P. Van Bortel L. Christiaens T. Home medication cabinets and self‐medication: a source of potential health threats?.Ann Pharmacother. 2008; 42: 572-9Crossref PubMed Scopus (0) Google Scholar]. In conclusion, even if a long‐term vascular effect of NSAIDs might be an explanation for the persistence of a cardiovascular risk during 6 months after cessation of prescription, actual cessation of intake should be proven first. In absence of this verification, one might also support the hypothesis of an increased immediate thrombotic risk related to the thromboxane/prostacycline imbalance induced by the COX‐2 inhibition, or to the different endothelial/platelet induced by COX‐1 inhibition, as proposed by the same authors in other papers [2Garcia Rodriguez L.A. Tacconelli S. Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti‐inflammatory drugs in the general population.J Am Coll Cardiol. 2008; 52: 1628-36Crossref PubMed Scopus (0) Google Scholar, 11García Rodríguez L.A. The effect of NSAIDs on the risk of coronary heart disease: fusion of clinical pharmacology and pharmacoepidemiologic data.Clin Exp Rheumatol. 2001; 19: S41-4PubMed Google Scholar]. The authors state that they have no conflict of interest." @default.
• W2085880083 created "2016-06-24" @default.
• W2085880083 creator A5010670616 @default.
• W2085880083 creator A5020558306 @default.
• W2085880083 creator A5027095105 @default.
• W2085880083 creator A5032986176 @default.
• W2085880083 creator A5056792374 @default.
• W2085880083 date "2009-09-01" @default.
• W2085880083 modified "2023-09-28" @default.
• W2085880083 title "NSAIDs discontinuation and myocardial infarction" @default.
• W2085880083 cites W1970351453 @default.
• W2085880083 cites W2020014363 @default.
• W2085880083 cites W2023995592 @default.
• W2085880083 cites W2026375486 @default.
• W2085880083 cites W2059830154 @default.
• W2085880083 cites W2094159068 @default.
• W2085880083 cites W2133900227 @default.
• W2085880083 cites W2165266539 @default.
• W2085880083 cites W2167601309 @default.
• W2085880083 cites W2167613032 @default.
• W2085880083 doi "https://doi.org/10.1111/j.1538-7836.2009.03542.x" @default.
• W2085880083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19602131" @default.
• W2085880083 hasPublicationYear "2009" @default.
• W2085880083 type Work @default.
• W2085880083 sameAs 2085880083 @default.
• W2085880083 citedByCount "1" @default.
• W2085880083 countsByYear W20858800832020 @default.
• W2085880083 crossrefType "journal-article" @default.
• W2085880083 hasAuthorship W2085880083A5010670616 @default.
• W2085880083 hasAuthorship W2085880083A5020558306 @default.
• W2085880083 hasAuthorship W2085880083A5027095105 @default.
• W2085880083 hasAuthorship W2085880083A5032986176 @default.
• W2085880083 hasAuthorship W2085880083A5056792374 @default.
• W2085880083 hasBestOaLocation W20858800831 @default.
• W2085880083 hasConcept C126322002 @default.
• W2085880083 hasConcept C164705383 @default.
• W2085880083 hasConcept C2778715236 @default.
• W2085880083 hasConcept C500558357 @default.
• W2085880083 hasConcept C71924100 @default.
• W2085880083 hasConceptScore W2085880083C126322002 @default.
• W2085880083 hasConceptScore W2085880083C164705383 @default.
• W2085880083 hasConceptScore W2085880083C2778715236 @default.
• W2085880083 hasConceptScore W2085880083C500558357 @default.
• W2085880083 hasConceptScore W2085880083C71924100 @default.
• W2085880083 hasIssue "9" @default.
• W2085880083 hasLocation W20858800831 @default.
• W2085880083 hasLocation W20858800832 @default.
• W2085880083 hasOpenAccess W2085880083 @default.
• W2085880083 hasPrimaryLocation W20858800831 @default.
• W2085880083 hasRelatedWork W2119852139 @default.
• W2085880083 hasRelatedWork W2165119695 @default.
• W2085880083 hasRelatedWork W2316107365 @default.
• W2085880083 hasRelatedWork W2367140913 @default.
• W2085880083 hasRelatedWork W2377483921 @default.
• W2085880083 hasRelatedWork W2384102316 @default.
• W2085880083 hasRelatedWork W2411183214 @default.
• W2085880083 hasRelatedWork W2443697580 @default.
• W2085880083 hasRelatedWork W2466043692 @default.
• W2085880083 hasRelatedWork W2595649087 @default.
• W2085880083 hasVolume "7" @default.
• W2085880083 isParatext "false" @default.
• W2085880083 isRetracted "false" @default.
• W2085880083 magId "2085880083" @default.
• W2085880083 workType "article" @default.